RxDoctor Payments Data

Vivek Narain, MD

Urology · Gallatin, TNNPI 1598743031

Payments from drug & device makers

$2,918in general payments, 2019–2025

Across 141 payments — averaging $20.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$592
  • Coloplast$443
  • Sumitomo Pharma America, Inc.$263
  • AbbVie$229
  • Tolmar Pharmaceuticals, Inc.$164
  • Neotract Inc.$137
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$2,61590%
  • Education$30310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,918 in reported general payments places this provider in the 45th percentile of 276 urology providers in Tennessee.

See all urology providers in Tennessee

Medicare billing

Part B allowed, 2024
$294,014
Medicare patients
624
Services billed
5,312

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix78$205,323
MyrbetriqMirabegron69$41,357
Potassium Citrate ErPotassium Citrate158$13,950
Solifenacin Succinate129$12,780
GemtesaVibegron18$12,600
PremarinEstrogens, Conjugated27$11,396
Tamsulosin Hcl913$11,315
Testosterone Cypionate163$7,440
Testosterone64$7,081
Finasteride497$6,933
Trimethoprim70$3,291
Bicalutamide63$2,061
Oxybutynin Chloride84$1,297
NitrofurantoinNitrofurantoin Macrocrystal60$1,246
Oxybutynin Chloride ErOxybutynin Chloride37$1,214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$263$217,92296 claims
Astellas Pharma US IncMyrbetriq$592$41,35769 claims
PfizerPremarin$135$11,39627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 276 urology providers in Tennessee.

Other urology in Gallatin

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →